IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study-Reference-Cited by-同舟云学术

IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study

Published:2007-03-29 Issue:1 Volume:5 Page:
ISSN:1476-8518
Container-title:Journal of Immune Based Therapies and Vaccines
language:en
Short-container-title:J Immune Based Ther Vaccines

Author:

Brignone Chrystelle,Grygar Caroline,Marcu Manon,Perrin Gaëlle,Triebel Frédéric

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Immunology

Link

https://link.springer.com/content/pdf/10.1186/1476-8518-5-5.pdf

Reference16 articles.

1. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR: Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A. 2003, 100: 12367-12371. 10.1073/pnas.2032886100.

2. El mir S, Triebel F: A soluble LAG-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol. 2000, 164: 5583-5589.

3. Andreae S, Piras F, Burdin N, Triebel F: Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol. 2002, 168: 3874-3880.

4. Buisson S, Triebel F: MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine receptor expression by human dendritic cells. Vaccine. 2003, 21: 862-868. 10.1016/S0264-410X(02)00533-9.

5. Prigent P, Mir SE, Dreano M, Triebel F: LAG-3 induces tumor regression and antitumor immune responses in vivo. Eur J Immunol. 1999, 29: 3867-3876. 10.1002/(SICI)1521-4141(199912)29:12<3867::AID-IMMU3867>3.0.CO;2-E.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LAG-3 in Cancer Immunotherapy: A Comprehensive Review;International Journal of Advanced Research in Science, Communication and Technology;2024-09-05

2. A Systematic Review of the Advances in the Study of T Lymphocyte Suppressor Receptors in HBV Infection: Potential Therapeutic Targets;Journal of Clinical Medicine;2024-02-21

3. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial;Clinical Cancer Research;2023-11-08

4. Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor;Cells;2022-07-30

5. Clinical landscape of LAG-3-targeted therapy;Immuno-Oncology and Technology;2022-06